Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 years or older.~* Laboratory-confirmed hereditary angioedema type I or II.~* Less than two hereditary angioedema attacks per month in the last three months.~* Body weight of 50.0 kg to 110.0 kg.~Exclusion Criteria:~* Receiving prophylactic C1-esterase inhibitor therapy.~* Received C1-esterase inhibitor, ecallantide, icatibant or any blood products for the prevention or treatment of hereditary angioedema within 7 days before the screening visit.~* Intends to use recombinant C1-esterase inhibitor or fresh frozen plasma for the acute treatment of hereditary angioedema during the study.~* Received androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 30 days before the screening visit.~* Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progesterone-containing products) within 3 months prior to the screening visit.~* Known or suspected hypersensitivity to the study product, or to any excipients of the study product.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low, then medium, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Medium, then low, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Medium, then high, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- Low, then high, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- High, then low, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None
- High, then medium, C1-esterase inhibitor dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).